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Abstract
Activity of the apolipoprotein B mRNA editing enzyme, catalytic-polypeptide-like (APOBEC) enzymes has been linked to 
specific mutational processes in human cancer genomes. A germline APOBEC3A/B deletion polymorphism is associated 
with APOBEC-dependent mutational signatures, and the deletion allele has been reported to confer an elevated risk of 
some cancers in Asian populations, while the results in European populations, so far, have been conflicting. We genotyped 
the APOBEC3A/B deletion polymorphism in a large population-based sample consisting of 11 106 Caucasian (Norwegian) 
individuals, including 7279 incident cancer cases (1769 breast, 1360 lung, 1585 colon, and 2565 prostate cancer) and a control 
group of 3827 matched individuals without cancer (1918 females and 1909 males) from the same population. Overall, the 
APOBEC3A/B deletion polymorphism was not associated with risk of any of the four cancer types. However, in subgroup 
analyses stratified by age, we found that the deletion allele was associated with increased risk for lung cancer among 
individuals <50 years of age (OR 2.17, CI 1.19–3.97), and that the association was gradually reduced with increasing age (P = 
0.01). A similar but weaker pattern was observed for prostate cancer. In support of these findings, the APOBEC3A/B deletion 
was associated with young age at diagnosis among the cancer cases for both cancer forms (lung cancer: P = 0.02; dominant 
model and prostate cancer: P = 0.03; recessive model). No such associations were observed for breast or colon cancer.
Introduction
Recent advances in cancer genome studies have identified 
several mutational signatures and mutational processes that 
point towards the molecular mechanisms behind mutations 
in cancer cell’s DNA (1–3). One of the most abundant signa-
tures has been found to emerge from the cytidine deaminase 
activity of proteins belonging to the apolipoprotein B mRNA 
editing enzyme, catalytic-polypeptide-like (APOBEC) family 
(1,4,5). The APOBEC mutational signatures observed in human 
cancers are particularly linked to the activity of the APOBEC3A 
and 3B proteins (6–8).
The APOBEC3 subfamily of proteins (APOBEC3A-G) is encoded 
by an APOBEC genomic cluster on chromosome 22 (9,10) and is 
known to protect human cells from viral infection by mutation 
of single-stranded DNA (10). While a link between the APOBEC3 
genes and DNA damage was suggested already in the beginning 
of the 2000s (reviewed in (11)), it was more recently established 
that APOBEC3A is capable of hypermutating nuclear DNA and 
induce double-stranded DNA breaks (12,13). It has also been 
suggested, although to a lesser extent, that APOBEC3B is able to 
edit genomic DNA (14).
Recently, a common germline 29.5 kb deletion in the 
APOBEC3 gene region was linked to an APOBEC-related mu-
tational signature in breast tumors (15). The 29.5 kb deletion 
removes the 3′ end of the APOBEC3A gene and a large part of 
the APOBEC3Bgene, creating a hybrid gene that transcribes an 
mRNA with the APOBEC3A coding region and the APOBEC3B 
3′-untranslated regions (16). This hybrid transcript is more 
stable than the wild-type; therefore, it may lead to increased 
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intracellular levels, with subsequent higher DNA damage 
caused by APOBEC3 activity (17). In population studies, the 
minor allele frequency (MAF) of the APOBEC3A/B deletion 
polymorphism has been estimated to 6% among individuals 
of European decent and 37% among individuals of Asian de-
cent (16). Case–control studies in Asian populations have found 
that the APOBCEC3A/B deletion allele may be associated with 
increased risk for breast and ovarian cancer (18–20). In 2013, 
Xuan et al. also reported that the APOBEC3A/B deletion variant 
may be associated with increased risk for breast cancer among 
European women (21); however, this finding was not repro-
duced in a Swedish study (22).
In the present study, we analysed a large sample (n = 11 106) 
of the population-based cohort of Norway and assessed the 
impact of APOBEC3A/B deletion genotype on risk of cancer in 
the breast, colon, prostate and lung, using a case-control design.
Materials and methods
Study population
All samples analysed were drawn from the population-based cohort of 
Norway (23). In the present study, we included 11 130 individuals. Among 
these, the molecular analysis failed in 24 samples due to technical rea-
sons, leaving 11 106 individuals for statistical analyses. These 11 106 
included 7279 incident cancer cases (1769 breast, 1360 lung, 1585 colon, 
and 2565 prostate cancer) and a control group consisting of 3827 matched 
individuals without cancer (1918 females and 1909 males) from the same 
cohort.
The selected samples have been described previously in detail in ger-
mline genotyping studies (24–27). In our previous studies 10 830 out of 
10 842 drawn samples were successfully analysed for MDM2 and MDM4 
germline SNPs. Due to lack of DNA, 51 of the previous samples were not 
included in the present analyses, while 339 new samples were added, gen-
erating the total sample of 11 130 individuals.
The study was approved by the Regional Committee for Ethics in 
Medical Research (REK Midt-Norge), and all sample donors had provided 
written informed consent to anonymous genetic testing for scientific 
purposes.
Sample size
Given the fact that the ABOBEC3A/B deletion occurs at a lower frequency 
among Caucasians than among Asians, we performed power estimates 
to ensure that our sample set was large enough to detect differences 
between cases and controls. Few data are available for Caucasians, but we 
based our estimates on previously published data for breast cancer cases 
and controls among women of European ancestry. Based on the findings 
reported by Xuan et al. (21), and applying an α-value of 0.05, we found our 
sample sizes to yield the following β-values: 0.83 for breast cancer, 0.76 for 
lung cancer, 0.91 for prostate cancer and 0.80 for colon cancer. As such, we 
considered the sample sizes to be adequate for analysis.
APOBEC3 ins/del genotyping
Eleven thousand one hundred and six samples were successfully geno-
typed for the ABOBEC3A/B deletion on a LightCycler 480 II instrument 
(Roche Diagnostics, Basel, Switzerland) using separate primer pairs 
for the deletion and the wild-type allele (16) and with the following 
hybridization probes: 5′-LC640-TGTCCCAGCAGTACTCAAACT-PH and 
5′-CATCCCTGGCGGTACACAA-FL for the wild-type allele and 5′-LC-640-
TGTCCCAGCAGTGCTTAAATT-PH and 5′-CATCCCTGGTGGTCCACAA-FL 
for the deletion allele (TIB MOLBIOL Syntheselabor GmbH, Berlin, 
Germany). The amplifications of the wild-type and deletion allele were 
performed separately, in a final reaction volume of 10 µl, containing 1 
µl LightCycler® FastStart DNA Master HybProbe mix (Roche Diagnostics, 
Basel, Switzerland), 3mM MgCl2, 0.125 µM of each probe and 0.5 µM or 0.1 
µM of each primer pairs, for the wild-type allele and the deletion allele, 
respectively, and finally, 0.05 U of Taq DNA polymerase (VWR) were added 
in the wild-type allele amplification. The thermocycling conditions were 
10 min initial denaturation/activation at 95°C, followed by 45 or 50 cycles 
of denaturation at 95°C for 15 s, annealing for 10 s at 55°C or 59°C and an 
elongation step at 72°C for 15 or 25 s for the deletion and wild-type allele, 
respectively. Prior to the cooling step at 40°C for 30 s, the high resolution 
melting (HRM) step was performed, starting with an initial denaturation 
at 95°C for 30 s, followed by melting from 40 to 85°C with a ramp rate of 
0.19°C/s. The HRM curve profiles were analysed applying the Melt Curve 
Genotyping module in the LightCycler® 480 II software version 1.5.
Subsequent to the HRM genotyping, the results from approximately 
6% of all samples were validated by an independent PCR assay, described 
in (16), detecting only the wild-type allele.
Furthermore, 10% of all samples were genotyped for the SNP 
rs12628403, which is located in close proximity to the ABOBEC3A/B dele-
tion, and reported previously to be in strong linkage disequilibrium with 
the deletion (28). The SNP was genotyped applying a custom LightSNiP 
assay (TIB-Molbiol) according to the manufacturer’s recommendation. The 
thermocycling conditions were 10 min initial denaturation/activation at 
95°C, followed by 45 cycles of denaturation at 95°C for 10 s, annealing for 
10 s at 60°C and an elongation step at 72°C for 30 s. Prior to the cooling 
step at 40°C for 30 s, the HRM step was performed, starting with an initial 
denaturation at 95°C for 30 s, followed by melting from 40°C to 75°C with 
a ramp rate of 2.0°C/s. The melting curve profiles were analysed applying 
the Melt Curve Genotyping module in the LightCycler® 480 II software 
version 1.5. Out of the samples genotyped for rs12628403 (n = 1104), 16 
revealed genotypes indicating recombination between this locus and the 
ABOBEC3A/B deletion. Four out of these 16 were reclassified when regard-
ing the results from the two assays together. Accordingly, we observed 
recombination in 12 (1.09%) of individuals, corresponding to 0.54% of 
alleles. This recombination rate was in line with previous observations in 
an American cohort (28).
Statistics
Potential deviations from the Hardy-Weinberg equilibrium were determined 
by using the Chi-square test. Possible associations between the APOBEC3A/B 
polymorphism and risk for cancer of the breast, colon, lung or prostate were 
estimated by odds ratios (ORs) applying logistic regression analyses. All ORs 
are given with 95% confidence intervals (CI). For breast and prostate cancer, 
we used female and male controls for risk estimation, respectively, and the 
ORs were adjusted for age. For colorectal cancer, ORs were adjusted for age 
and sex. In addition, we here performed sex-specific sub-analyses, where 
female and male cases were compared to female and male controls. These 
sub-analyses were adjusted for age as co-variate. For lung cancer, ORs were 
adjusted for age, sex and smoking. In addition, we here performed sex-
specific sub-analyses adjusted for age and smoking. When multiple adjust-
ments were made, the interaction terms between the variables were also 
included in the models. The applied adjustments are given as footnotes in 
Table 1. Trends for ORs across age groups were estimated using binary logis-
tic regression. Potential differences in age at onset of cancer were estimated 
by the Mann-Whitney rank test. The statistical analyses were performed 
using the IBM SPSS 22 software (IBM Corp, Armonk, NY, USA).
Results
Distribution of APOBEC3A/B genotypes
Among 3827 controls, we found 3148 individuals (82.3%) to be 
homozygous for the APOBEC3A/B insertion allele, 635 (16.6%) to be 
heterozygous, while 44 (1.2%) were homozygous for the deletion 
allele (Table 1). This resulted in an observed MAF of 0.094 and a gen-
otype distribution that did not deviate from the Hardy-Weinberg 
Abbreviations 
APOBEC  apolipoprotein B mRNA editing enzyme,   
 catalytic-polypeptide-like
CI  confidence intervals
HRM  high resolution melting
MAF  minor allele frequency
ORs  odds ratios.
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equilibrium (P > 0.4). The distributions of genotypes were also found 
to be in Hardy-Weinberg equilibrium within the groups of patients 
diagnosed with each of the four cancer types (all P-values > 0.4).
APOBEC3A/B genotypes and cancer risk
The distribution of the APOBEC3A/B genotypes in the different 
cancer types is given in detail in Table 1. We found no clear asso-
ciation between APOBEC3A/B genotype and risk of any of the 
four investigated cancer forms either applying the dominant or 
the recessive model (Table 1A; Figure 1).
For lung and colorectal cancer, we performed sub-analyses 
stratified according to sex but observed no association between 
the APOBEC3A/B variant and cancer risk for any of the sex-
specific subgroups (Table 1A; Figure 1). For lung cancer, we 
performed additional analyses stratified by smoking status; 
the vast majority of lung cancer cases was confirmed smokers 
(87.3%), and the results in the smoker/non-smoker subgroups 
did not differ from the overall lung cancer analyses (data not 
shown). Similar results were obtained when assessing the allele 
distributions (Table 1B).
Figure 1. APOBEC3A/B deletion and cancer risk. Forest plot illustrating the ORs for cancer of the colon, lung, breast and prostate, related to the APOBEC3A/B deletion 
polymorphism (dominant model).
Table 1A. APOBEC3A/B genotype and cancer risk
Cases/controls
Genotype n (%)
OR (95% CI) 
Dominanta P
OR (95% CI) 
Recessiveb Pins/ins ins/del del/del
Controls 3148 (82.3) 635 (16.6) 44 (1.2) 1.00 – 1.00 –
 Females 1576 (82.2) 322 (16.8) 20 (1.0) 1.00 – 1.00 –
 Males 1572 (82.4) 313 (16.4) 24 (1.3) 1.00 – 1.00 –
Colon cancerc 1322 (83.4) 250 (15.8) 13 (0.8) 0.91 (0.77−1.08) 0.28 0.71 (0.37−1.36) 0.30
 Femalesd 679 (84.2) 120 (14.9) 7 (0.9) 0.85 (0.67−1.08) 0.19 0.95 (0.37−2.42) 0.92
 Malese 643 (82.5) 130 (16.7) 6 (0.8) 0.97 (0.77−1.22) 0.81 0.55 (0.22−1.38) 0.20
Lung cancerf 1101 (81.0) 240 (17.7) 19 (1.4) 1.13 (0.94−1.36) 0.20 1.03 (0.54−1.97) 0.93
 Femalesg 405 (80.0) 98 (19.4) 3 (0.6) 1.22 (0.90−1.67) 0.20 0.84 (0.22−3.18) 0.80
 Malesh 696 (81.5) 142 (16.6) 16 (1.9) 1.08 (0.85−1.36) 0.54 1.11 (0.52−2.34) 0.79
Breast cancerd 1465 (82.8) 292 (16.5) 12 (0.7) 0.95 (0.80−1.13) 0.57 0.64 (0.31−1.31) 0.22
Prostate cancere 2148 (83.7) 390 (15.2) 27 (1.1) 0.93 (0.78−1.10) 0.37 0.96 (0.53−1.74) 0.89
aDominant model: del/del + ins/del versus ins/ins.
bRecessive model: del/del versus ins/del + ins/ins.
cORs adjusted for age and sex.
dORs calculated against female controls and adjusted for age.
eORs calculated against male controls and adjusted for age.
fORs adjusted for age, sex and smoking.
gORs calculated against female controls and adjusted for age and smoking.
hORs calculated against male controls and adjusted for age and smoking.
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In sub-analyses, we estimated the OR for cancer in differ-
ent age groups (10  year intervals). For both lung and prostate 
cancer, applying the dominant model, we found that the asso-
ciation (OR) for the deletion allele decreased with age: For lung 
cancer, we found an increased risk among individuals <50 years 
of age (OR = 2.17; CI = 1.19–3.97; Figure 2), in addition to a gradual 
decrease in the OR with increasing age (P for trend = 0.01). Again, 
stratified analyses according to smoking status did not differ 
from the overall lung cancer analyses within age groups (data 
not shown). However, stratifying for gender, we found the asso-
ciation to be stronger among females (OR = 2.58; CI = 1.19–5.57) 
than among males (OR = 1.52; CI = 0.57–4.08; Supplementary Table 
S1, available at Carcinogenesis Online; P = 0.002 for the interaction 
between age and gender in a multivariate risk model). A similar 
but weaker pattern was observed for prostate cancer: here, the 
highest OR was present in men <50 years of age, followed by a 
reduction in the OR with increasing age. However, this trend did 
not reach statistical significance (P = 0.31: Figure 2) and neither 
did the interaction between age and gender (P = 0.12).
For breast and colorectal cancer, we found no similar pat-
terns of risk associated with the deletion allele across age 
groups (Figure 2).
APOBEC3A/B genotypes and age at cancer onset
We also assessed whether the APOBEC3A/B genotype status of 
patients was associated with age at diagnosis within each of the 
four cancer groups.
Among patients diagnosed with lung cancer, age at diagno-
sis was lower among individuals harbouring the deletion allele, 
as compared to individuals with the homozygous insertion 
genotype (dominant model: P = 0.02, Mann-Whitney rank test; 
Table 2; Figure 3). Similar results were observed for prostate can-
cer, albeit here, the reduced age at diagnosis was observed in 
the recessive model (P = 0.03, Mann-Whitney rank test; Table 
2; Figure 3). For breast and colon cancer cases, we observed no 
association of APOBEC3A/B status and age at diagnosis.
Figure 2. APOBEC3A/B deletion and age-related cancer risk. ORs for cancer of the colon, lung, breast and prostate, related to the APOBEC3A/B deletion polymorphism 
within age 10 years interval age groups (dominant model).
Table 1B. APOBEC3A/B alleles and cancer risk
Cases/controls
Alleles n (%)
OR (95% CI) Pins del
Controls 6931 (90.6) 723 (9.5) 1.00 –
 Females 3474 (90.6) 362 (9.4) 1.00 –
 Males 3457 (90.5) 361 (9.5) 1.00 –
Colon cancera 2894 (91.3) 276 (8.7) 0.91 (0.78−1.06) 0.21
 Femalesb 1478 (91.7) 134 (8.3) 0.87 (0.69−1.09) 0.21
 Malesc 1416 (90.9) 142 (9.1) 0.94 (0.76−1.17) 0.58
Lung cancerd 2442 (89.8) 278 (10.2) 1.11 (0.94−1.32) 0.23
 Femalese 908 (89.7) 104 (10.3) 1.18 (0.89−1.57) 0.26
 Malesf 1534 (89.8) 174 (10.2) 1.07 (0.87−1.33) 0.52
Breast cancerb 3222 (91.1) 316 (8.9) 0.94 (0.82−1.08) 0.39
Prostate cancerc 4686 (91.4) 444 (8.7) 0.92 (0.80−1.05) 0.23
aORs adjusted for age and sex.
bORs calculated against female controls and adjusted for age.
cORs calculated against male controls and adjusted for age.
dORs adjusted for age, sex and smoking.
eORs calculated against female controls and adjusted for age and smoking.
fORs calculated against male controls and adjusted for age and smoking.
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Discussion
In this population-based case-control study, we assessed 
whether the APOBEC3A/B deletion polymorphism is associated 
with the risk for cancer of the breast, colon, lung and prostate, 
using a large sample of Norwegian individuals. Although the 
Norwegian population is very homogenous and might not be 
representative for all Caucasians, our observation of a MAF of 
0.094 is in line with previous observations in case-control stud-
ies performed on European cohorts (21,22). Overall, we found no 
association between the deletion polymorphism and cancer risk 
for any of the four cancer forms (breast, lung, colon or prostate). 
However, for lung cancer, we made interesting observations in 
different age groups, where an elevated cancer risk associated 
with the deletion allele was found in individuals younger than 
50 years of age, and where the OR gradually decreased with 
increasing age. Similar but weaker findings were made for pros-
tate cancer. These results were corroborated by the fact that for 
both cancers, the deletion allele was associated with younger 
Table 2. APOBEC3A/B genotype and age at cancer diagnosis
Diagnosis Genotype n
Mean 
age 
(years)
P-valuea 
(dominant 
model)
P-valuea 
(recessive 
model)
Colon cancer ins-ins 1322 70.9
ins-del 250 71.5
del-del 13 69.6 >0.5 >0.5
Lung cancer ins-ins 1101 70.3
ins-del 240 68.3
del-del 19 71.0 0.02 >0.5
Breast cancer ins-ins 1465 60.4
ins-del 292 60.1
del-del 12 62.1 >0.5 >0.5
Prostate cancer ins-ins 2148 71.8
ins-del 390 71.6
del-del 27 67.6 >0.5 0.03
aMann–Whitney rank test.
Figure 3. APOBEC3A/B deletion and age at diagnosis. (A) Cumulative fraction of patients with lung cancer diagnoses among individuals harbouring the APOBEC3A/B 
deletion allele (red diamonds) and individuals homozygous for the insertion allele (blue diamonds), plotted against age at lung cancer diagnosis. (B) Cumulative frac-
tion of patients with prostate cancer diagnoses among individuals homozygous for the APOBEC3A/B deletion allele (red diamonds) and individuals heterozygous or 
homozygous for the insertion allele (blue diamonds), plotted against age at prostate cancer diagnosis.
Downloaded from https://academic.oup.com/carcin/article-abstract/39/2/118/4626621
by guest
on 18 July 2018
L.B.Gansmo et al. | 123
age at diagnosis among the patients. Although these findings 
are striking, the underlying mechanisms are unknown.
Our finding that the APOBEC3A/B deletion may have a 
particular effect on lung cancer risk is in line with previous 
observations of the mutational signature linked to APOBEC 
activity in lung cancer genomes (1). However, while this sig-
nature has also been identified in breast cancer (1), and the 
magnitude of APOBEC-related mutation load in this cancer 
type has been linked to the APOBEC3A/B deletion (15), we did 
not observe any clear impact of the deletion variant on breast 
cancer risk.
While previous studies have reported the APOBECA/B dele-
tion allele to be associated with increased risk for breast can-
cer (18,20,21), our observations are in line with a recent Swedish 
study reporting no association between APOBECA/B genotype 
and breast cancer risk (22). Notably, the discrepancy between 
studies could, at least partly, be due to ethnic differences since 
the Norwegian and Swedish populations are genetically very 
similar, while most positive studies (18,20) have been performed 
in Asian populations.
Although the hybrid transcript resulting from APOBEC3A/B 
deletion polymorphism has been found more stable than 
the wild-type transcript (17) and this indicate a real func-
tional role of the polymorphism, the possibility exist that the 
APOBEC gene cluster also harbour other important polymor-
phisms and that haplotypes across several variants need to 
be taken into account when assessing germline genotype and 
cancer risk associated with APOBEC activity. Notably, there are 
several SNPs in the APOBEC gene family, including rs5750715, 
rs5757402 and rs17370615 that are also unequally distributed 
between ethnic groups, with MAFs of 0.27, 0.38, 0.29 and 0.47, 
0.04, 0.04 among Caucasians and Asians, respectively (29). 
Recently, it was reported that the APOBEC3A/B deletion vari-
ant was associated with decreased risk of bladder cancer; 
however, after adjusting the risk estimates for the effect of 
SNP rs1014971 (a SNP found 20 kb upstream of APOBEC3A, this 
association) was lost (28). Of note, similar effects have been 
reported for other germline variants linked to cancer risk, e.g. 
the MDM2 promoter polymorphism SNP309 rs2279744 (30), 
where the minor allele has been linked to increased risk of 
several cancers, particularly in Asian populations (31), while 
in Caucasian studies, the effect seems to be ‘confounded’ 
by other SNPs in the same region, which are only present in 
Caucasians (32,33).
In the present study, we performed several sub-analyses with 
stratification according to gender, and for lung cancer, we also 
stratified the data according to smoking status. While none of 
these sub-analyses revealed effects of the APOBEC3A/B deletion 
polymorphism on risk of colon or lung cancer, it may well be 
that further stratification of the four cancer types in the present 
study, if possible, could have revealed different results. Notably, 
the above mentioned APOBEC-related SNP rs1014971 has been 
found to affect the risk of estrogen receptor-positive breast can-
cers, in particular (28). However, such data were not available in 
the CONOR cohort.
In conclusion, we found that the APOBEC3A/B deletion poly-
morphism is associated with increased risk of lung cancer in 
individuals younger than 50 years of age and a younger age at 
diagnosis among lung and prostate cancer patients carrying this 
germline variant.
Supplementary material
Supplementary Table S1 can be found Carcinogenesis online.
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